07:44 AM EST, 12/02/2025 (MT Newswires) -- Tiziana Life Sciences ( TLSA ) said Tuesday it plans to spin out its anti-IL-6 receptor monoclonal antibody, TZLS-501, along with related assets, into a separate publicly traded entity.

The company said Tiziana shareholders as of the record date will retain value in TZLS-501 through a distribution in specie of shares in the new listed company.

Tiziana said it views TZLS-501 as having "the potential to be a standalone business" and added that the spinout proposal will be subject to shareholder approval. Until the approval is granted, TZLS-501 will remain an asset of Tiziana Life Sciences ( TLSA ).

Tiziana Life Sciences ( TLSA ) shares were down more than 5% in recent Tuesday pre-bell activity.